Skip to main content

Main menu

  • Home
  • Articles
    • Current
    • Published Ahead of Print
    • Archive
    • Supplemental Issues
    • Collections - French
    • Collections - English
  • Info for
    • Authors & Reviewers
    • Submit a Manuscript
    • Advertisers
    • Careers & Locums
    • Subscribers
    • Permissions
  • About CFP
    • About CFP
    • About the CFPC
    • Editorial Advisory Board
    • Terms of Use
    • Contact Us
  • Feedback
    • Feedback
    • Rapid Responses
    • Most Read
    • Most Cited
    • Email Alerts
  • Blogs
    • Latest Blogs
    • Blog Guidelines
    • Directives pour les blogues
  • Mainpro+ Credits
    • About Mainpro+
    • Member Login
    • Instructions
  • Other Publications
    • http://www.cfpc.ca/Canadianfamilyphysician/
    • https://www.cfpc.ca/Login/
    • Careers and Locums

User menu

  • My alerts

Search

  • Advanced search
The College of Family Physicians of Canada
  • Other Publications
    • http://www.cfpc.ca/Canadianfamilyphysician/
    • https://www.cfpc.ca/Login/
    • Careers and Locums
  • My alerts
The College of Family Physicians of Canada

Advanced Search

  • Home
  • Articles
    • Current
    • Published Ahead of Print
    • Archive
    • Supplemental Issues
    • Collections - French
    • Collections - English
  • Info for
    • Authors & Reviewers
    • Submit a Manuscript
    • Advertisers
    • Careers & Locums
    • Subscribers
    • Permissions
  • About CFP
    • About CFP
    • About the CFPC
    • Editorial Advisory Board
    • Terms of Use
    • Contact Us
  • Feedback
    • Feedback
    • Rapid Responses
    • Most Read
    • Most Cited
    • Email Alerts
  • Blogs
    • Latest Blogs
    • Blog Guidelines
    • Directives pour les blogues
  • Mainpro+ Credits
    • About Mainpro+
    • Member Login
    • Instructions
  • RSS feeds
  • Follow cfp Template on Twitter
Research ArticlePractice

Hyperthyroidism during pregnancy

Miho Inoue, Naoko Arata, Gideon Koren and Shinya Ito
Canadian Family Physician July 2009, 55 (7) 701-703;
Miho Inoue
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Naoko Arata
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gideon Koren
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Shinya Ito
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • eLetters
  • Info & Metrics
  • PDF
Loading

ABSTRACT

QUESTION I have a 33-year-old patient with hyperthyroidism who is 6 weeks pregnant. Her thyroid function is well controlled with a 5-mg dose of methimazole 3 times daily. She was initially treated with propylthiouracil but was switched to methimazole owing to urticaria. I have heard about birth defects in infants whose mothers used methimazole during pregnancy. How safe is it?

ANSWER In North America, propylthiouracil has been the drug of choice for hyperthyroidism during pregnancy. Methimazole is widely used in Europe, South America, and Asia, and is an alternative for patients who cannot tolerate propylthiouracil. Some case reports raised concern about fetal toxicity from methimazole, which is reportedly characterized by aplasia cutis, esophageal atresia, choanal atresia, facial abnormalities, and mental retardation. However, causality is unclear and the overall risk of congenital abnormalities in infants exposed to methimazole in utero was not higher than in those exposed to nonteratogenic drugs in cohort studies. It is important for a pregnant woman to continue methimazole, if necessary, because uncontrolled hyperthyroidism increases the risk of complications such as preterm labour and low birth weight.

Hyperthyroidism occurs in 1 to 2 of every 1000 pregnant women.1 The most common cause of hyper-thyroidism (80% to 85%) is Graves disease. Other causes include functioning adenoma, thyroiditis, and excessive thyroid hormone intake. Clinical practice guidelines for the management of hyperthyroidism during pregnancy have been developed by academic societies, including the Endocrine Society, American Association of Clinical Endocrinologists, and American College of Obstetricians and Gynecologists.2–4

Hyperthyroidism caused by Graves disease tends to get worse during the first trimester, improve later in pregnancy, and get worse again after delivery. Placental human chorionic gonadotropin is structurally similar to thyroid-stimulating hormone (TSH), and the increase in human chorionic gonadotropin in the first trimester has been suggested to be the cause of thyroid stimulation. As pregnancy progresses, patients usually require lower doses of antithyroid drugs. Close monitoring of thyroid function needs to be continued after delivery in anticipation of postpartum exacerbation until the patient reaches a stable euthyroid state.

Fetal thyroid function

The fetus is dependent on the small supply of thyroxine (T4) from the mother until 10 to 12 weeks of gestation, when the fetal thyroid gland starts secreting thyroid hormones. By 20 weeks of gestation, the fetal thyroid gland becomes responsive to TSH from its own pituitary gland, but the function of the thyroid gland remains T4 across the relatively low. While transfer of maternal placenta is limited and the serum T4 level in a fetus is about one-third of the maternal level, maternal TSH-receptor antibodies in Graves disease are immunoglobulin G antibodies and readily cross the placenta. As a result, maternal TSH-receptor antibodies can cause fetal hyperthyroidism after 20 weeks of gestation. Antithyroid drugs, such as methimazole and propylthiouracil, also cross the placenta and therefore serve as treatment for both maternal and fetal hyperthyroidism.

Complications

Uncontrolled hyperthyroidism is associated with serious maternal, fetal, and neonatal morbidity, and mortality. Maternal complications include miscarriage, pregnancy-induced hypertension, preterm labour, placental abruption, heart failure, and thyroid storm. Fetal and neonatal complications include stillbirth, low birth weight, goiter, hyperthyroidism, and hypothyroidism.5–7 These risks can be decreased with the appropriate treatment of maternal hyperthyroidism.5

Management

Hyperthyroidism during pregnancy should be treated with an antithyroid drug. The goal of treatment is to maintain maternal free T4 in the upper normal range, using the lowest possible dose of the antithyroid drug. This approach aims at minimizing the risk of fetal hypothyroidism.8 Thyroid hormones are critical for fetal brain development, and caution against overtreatment is warranted. Mild hyperthyroidism is usually monitored closely without therapy as long as both the mother and the fetus are not symptomatic. If thyroidectomy is indicated for treatment failure with a high-dose antithyroid drug or adverse effects from an antithyroid drug, it is optimally performed during the second trimester of pregnancy. Radioactive iodine is contraindicated during pregnancy, as it readily crosses the placenta and is taken up in the fetal thyroid gland. For pregnant women with past or current Graves disease, Doppler examination of the fetal thyroid gland is useful in detecting goiter, which is associated with fetal hyperthyroidism or hypothyroidism.9

Antithyroid drugs during pregnancy

Propylthiouracil is the drug of choice for hyperthyroidism during pregnancy in North America owing to the suspected association of methimazole with congenital abnormalities (sometimes referred to as methimazole embryopathy), characterized by aplasia cutis, esophageal atresia, choanal atresia, facial abnormalities, and developmental delay. Since the association of methimazole with aplasia cutis was first suggested by an epidemiological study,10 cases of aplasia cutis or other associated abnormalities in infants exposed to methimazole in utero have been reported in the literature.11–13 However, in a prospective cohort study in which 241 women used methimazole and 1089 women used non-teratogenic drugs, the overall risk of serious congenital abnormalities in infants in the methimazole group was not higher than in those in the nonteratogenic drug group.14 In addition, 2 retrospective studies did not find an increase in congenital abnormalities in infants exposed to methimazole in utero.15,16 Another reason for the preference of propylthiouracil over methimazole is that a small study reported limited transplacental passage of propylthiouracil compared with methimazole.17 This finding was refuted by a later study.18 The risk of fetal hypothyroidism was not different between women with Graves disease taking propylthiouracil and those taking methimazole.19 Methimazole has been widely used in Europe, South America, and Asia and is an alternative to propylthiouracil in North America for patients with hyperthyroidism who cannot tolerate propylthiouracil.

Antithyroid drugs during lactation

Propylthiouracil is often recommended as the antithyroid drug of choice during lactation because the transfer of propylthiouracil to a nursing infant via breast milk seems to be less than the transfer of methimazole. However, neither propylthiouracil nor methimazole seem to pose a serious risk to nursing infants. A study that included 139 lactating mothers taking methimazole and their nursing infants showed no adverse effects on thyroid function or neurodevelopment of the infants.20 Methimazole doses of up to 20 mg/d did not cause hypothyroidism in nursing infants.21 Until more studies are available, thyroid function of nursing infants should be monitored if the mother receives a high dose of methimazole during lactation.

Conclusion

Propylthiouracil is the drug of choice for hyperthyroidism during pregnancy; however, methimazole is an alternative for patients who cannot tolerate propylthiouracil. Although there are case reports of fetal toxicity from methimazole, the overall risk of congenital abnormalities in infants exposed to methimazole in utero does not seem to be higher than those exposed to non-teratogenic drugs or propylthiouracil. It is important for a pregnant woman to continue methimazole, if necessary, because uncontrolled hyperthyroidism increases the risk of complications such as preterm labour and low birth weight.

MOTHERISK

Motherisk questions are prepared by the Motherisk Team at the Hospital for Sick Children in Toronto, Ont. Drs Inoue, Arata, and Ito are members and Dr Koren is Director of the Motherisk Program. Dr Koren is supported by the Research Leadership for Better Pharmacotherapy during Pregnancy and Lactation. He holds the Ivey Chair in Molecular Toxicology in the Department of Medicine at the University of Western Ontario in London.

Do you have questions about the effects of drugs, chemicals, radiation, or infections in women who are pregnant or breastfeeding? We invite you to submit them to the Motherisk Program by fax at 416 813-7562; they will be addressed in future Motherisk Updates.

Published Motherisk Updates are available on the Canadian Family Physician website (www.cfp.ca) and also on the Motherisk website (www.motherisk.org).

Footnotes

  • Competing interests

    None declared

  • Copyright© the College of Family Physicians of Canada

References

  1. ↵
    NealeDBurrowGThyroid disease in pregnancyObstet Gynecol Clin North Am2004314893905xi
    OpenUrlPubMed
  2. ↵
    BaskinHJCobinRHDuickDSGharibHGuttlerRBKaplanMMAmerican Association of Clinical Endocrinologists medical guidelines for clinical practice for the evaluation and treatment of hyperthyroidism and hypothyroidismEndocr Pract20028645769
    OpenUrlPubMed
  3. American College of Obstetricians and GynecologistsACOG practice bulletin. Clinical management guidelines for obstetrician-gynecologists. Number 37, August 2002. (Replaces practice bulletin Number 32, November 2001). Thyroid disease in pregnancyObstet Gynecol2002100238796
    OpenUrlCrossRefPubMed
  4. ↵
    AbalovichMAminoNBarbourLACobinRHDe GrootLJGlinoerDManagement of thyroid dysfunction during pregnancy and postpartum: an Endocrine Society clinical practice guidelineJ Clin Endocrinol Metab2007928 SupplS147
    OpenUrlCrossRefPubMed
  5. ↵
    MillarLKWingDALeungASKooningsPPMontoroMNMestmanJHLow birth weight and preeclampsia in pregnancies complicated by hyperthyroidismObstet Gynecol19948469469
    OpenUrlPubMed
  6. KriplaniABucksheeKBhargavaVLTakkarDAmminiACMaternal and perinatal outcome in thyrotoxicosis complicating pregnancyEur J Obstet Gynecol Reprod Biol199454315963
    OpenUrlCrossRefPubMed
  7. ↵
    DavisLELucasMJHankinsGDRoarkMLCunninghamFGThyrotoxicosis complicating pregnancyAm J Obstet Gynecol198916016370
    OpenUrlPubMed
  8. ↵
    MomotaniNNohJOyanagiHIshikawaNItoKAntithyroid drug therapy for Graves’ disease during pregnancy. Optimal regimen for fetal thyroid statusN Engl J Med19863151248
    OpenUrlPubMed
  9. ↵
    LutonDLe GacIVuillardECastanetMGuibourdencheJNoelMManagement of Graves’ disease during pregnancy: the key role of fetal thyroid gland monitoringJ Clin Endocrinol Metab2005901160938Epub 2005 Aug 23
    OpenUrlCrossRefPubMed
  10. ↵
    Martínez-FríasMLCereijoARodríguez-PinillaEUriosteMMethimazole in animal feed and congenital aplasia cutisLancet199233987957423
    OpenUrlPubMed
  11. ↵
    ClementiMDi GianantonioEPeloEMammiIBasileRTTenconiRMethimazole embryopathy: delineation of the phenotypeAm J Med Genet1999831436
    OpenUrlCrossRefPubMed
  12. ValdezRMBarberoPMLiascovichRCDe RosaLFAguirreMAAlbaLGMethimazole embryopathy: a contribution to defining the phenotypeReprod Toxicol20072322535Epub 2006 Nov 28
    OpenUrlCrossRefPubMed
  13. ↵
    BarberoPRicagniCMercadoGBronbergRTorradoMChoanal atresia associated with prenatal methimazole exposure: three new patientsAm J Med Genet A2004129A1836
    OpenUrl
  14. ↵
    Di GianantonioESchaeferCMastroiacovoPPCournotMPBenedicentiFReuversMAdverse effects of prenatal methimazole exposureTeratology20016452626
    OpenUrlCrossRefPubMed
  15. ↵
    MomotaniNItoKHamadaNBanYNishikawaYMimuraTMaternal hyperthyroidism and congenital malformation in the offspringClin Endocrinol (Oxf)1984206695700
    OpenUrlPubMed
  16. ↵
    WingDAMillarLKKooningsPPMontoroMNMestmanJHA comparison of propylthiouracil versus methimazole in the treatment of hyperthyroidism in pregnancyAm J Obstet Gynecol19941701 Pt 1905
    OpenUrlPubMed
  17. ↵
    MarchantBBrownlieBEHartDMHortonPWAlexanderWDThe placental transfer of propylthiouracil, methimazole and carbimazoleJ Clin Endocrinol Metab1977456118793
    OpenUrlCrossRefPubMed
  18. ↵
    MortimerRHCannellGRAddisonRSJohnsonLPRobertsMSBernusIMethimazole and propylthiouracil equally cross the perfused human term placental lobuleJ Clin Endocrinol Metab19978293099102
    OpenUrlCrossRefPubMed
  19. ↵
    MomotaniNNohJYIshikawaNItoKEffects of propylthiouracil and methimazole on fetal thyroid status in mothers with Graves’ hyperthyroidismJ Clin Endocrinol Metab1997821136336
    OpenUrlCrossRefPubMed
  20. ↵
    AziziFKhoshniatMBahrainianMHedayatiMThyroid function and intellectual development of infants nursed by mothers taking methimazoleJ Clin Endocrinol Metab200085932338
    OpenUrlCrossRefPubMed
  21. ↵
    AziziFHedayatiMThyroid function in breast-fed infants whose mothers take high doses of methimazoleJ Endocrinol Invest20022564936
    OpenUrlPubMed
PreviousNext
Back to top

In this issue

Canadian Family Physician: 55 (7)
Canadian Family Physician
Vol. 55, Issue 7
1 Jul 2009
  • Table of Contents
  • About the Cover
  • Index by author
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on The College of Family Physicians of Canada.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Hyperthyroidism during pregnancy
(Your Name) has sent you a message from The College of Family Physicians of Canada
(Your Name) thought you would like to see the The College of Family Physicians of Canada web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Hyperthyroidism during pregnancy
Miho Inoue, Naoko Arata, Gideon Koren, Shinya Ito
Canadian Family Physician Jul 2009, 55 (7) 701-703;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Respond to this article
Share
Hyperthyroidism during pregnancy
Miho Inoue, Naoko Arata, Gideon Koren, Shinya Ito
Canadian Family Physician Jul 2009, 55 (7) 701-703;
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • ABSTRACT
    • Fetal thyroid function
    • Complications
    • Management
    • Antithyroid drugs during pregnancy
    • Antithyroid drugs during lactation
    • Conclusion
    • Footnotes
    • References
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

Practice

  • Is 45 the new 50 in colorectal cancer screening?
  • Approach to diagnosis and management of childhood attention deficit hyperactivity disorder
  • Determining if and how older patients can safely stay at home with additional services
Show more Practice

Motherisk Update

  • Hepatitis A infection during pregnancy
  • Fluconazole use during breastfeeding
  • Is it safe to breastfeed while taking methylphenidate?
Show more Motherisk Update

Similar Articles

Navigate

  • Home
  • Current Issue
  • Archive
  • Collections - English
  • Collections - Française

For Authors

  • Authors and Reviewers
  • Submit a Manuscript
  • Permissions
  • Terms of Use

General Information

  • About CFP
  • About the CFPC
  • Advertisers
  • Careers & Locums
  • Editorial Advisory Board
  • Subscribers

Journal Services

  • Email Alerts
  • Twitter
  • RSS Feeds

Copyright © 2023 by The College of Family Physicians of Canada

Powered by HighWire